causal

Off-label mandate distorts the cancer drug market

A well-intentioned policy that let expert panels create registries of off-label drug use—originally sensible for older, cheap, off-patent cytotoxics with no sponsor to seek formal approval—has been captured by makers of $100-200k drugs who gain market share through expert recommendations, since Medicare is wedded to pay for off-label uses at certain evidence levels and cannot say no even when the evidence is flimsy or absent.

causalpending

Speaker

Vinay Prasad

Evidence Quote

“this system that was well-intentioned, that works for older, cheaper drugs, kind of has been taken over by newer $100,000-, $200,000-drugs that are extremely lucrative to the manufacturer”

Source

Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant— EconTalk
Created: 6/13/2026, 12:28:36 AM

Your notes

Loading notes...